Rigel Pharmaceuticals | RIGL - Operating Expenses


Rigel Pharmaceuticals reported $117.61M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD -221.22M 241.03M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celldex Therapeutics USD 456.23M 368.95M Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Veracyte USD 119.99M 3.99M Mar/2026